Challenging an over 100-year-old histology technic that is prone to false negatives.

In cancer diagnostics.

My guest aims to take histopathology departments from the 20th century into the 21st century, where they belong.

From slicing biopsy samples into 3D.

From a manual preparation to a robotic one.

Where all abnormalities will be pointed out and counted by AI.

And human physicians will see inside the whole sample in 3D.

Let's get down to the cell level.

You’ll hear

• what happens to your biopsy samples
• why the current histopathology standard is prone to misses
• how do you see inside the tissue in 3D and see 400 times more cells
• what’s so fascinating about watching cells and tissues under the microscope
• and more

Dr. Francesca Catto, the CEO of IMAI. With a background in Medical Biotechnology and Molecular Medicine, she fell in love with histopathology just to challenge it, when her research showed the current ways are not enough.

IMAI is a pre-seed stage Swiss medtech startup. They develop an automated robotic platform for faster 3D analysis of tumor tissues. Supported with AI, they avoid false negatives and offer better cancer detection.

https://www.imai-medtech.com/

If you've enjoyed listening, you'll make us happy by clicking "Follow" on X-Health.show and leaving a review.

The information in this podcast is for informational purposes only and should not be considered medical advice. If you have any medical questions, please consult your healthcare practitioner. The opinions on the show are Alex's or her guests. The podcast does not make any responsibility or warranties about guests statements or credibility. While the podcast makes every effort to ensure that the information shared is accurate, please let us know if you have any comments, suggestions or corrections.